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ABSTRACT 
 
In the last decades, ionic liquids (ILs) progressed from chemical curiosities to 
interesting biological compounds apprehending the attention of researchers of distinct 
areas, from chemistry to pharmacology.  
Initially, ILs were explored as materials for diverse applications due to the possibility 
of synthesize compounds with targeted chemical properties combined with selected 
physical properties. More recently, the emergence of ILs with biological activity 
revolutionized the scientific focus of these compounds and opened interesting 
perspectives regarding their pharmaceutical application. From the pharmaceutical point 
of view, an IL approach, in the design of novel active pharmaceutical ingredients (APIs), 
appears to be appropriate as it enables the chemical manipulation of the compounds with 
specific objectives related with the manufacturing process, the stability of the 
formulation, bioavailability and eventual adverse effects. Furthermore, even though 
crystallinity confers advantages during isolation, processing and storage of the drug, it is 
known that solid forms of APIs often suffer from low solubility and polymorphic 
conversion which can influence negatively the bioavailability of the drug and ultimately 
its therapeutic effect.  
On a distinct perspective, the possibility of engineering the properties of ILs by 
manipulating anion-cation combinations, in association with their solvent properties and 
in some cases water-miscibility, are considered promising characteristics regarding the 
applicability of ILs as solvents or carriers of pharmaceutical drugs.  
In this chapter it is intended to expose the pharmaceutical potential of ILs through 
the discussion of their utilization either as APIs or solvents/carriers of pharmaceutical 
drugs. The discussion will be centered on the benefits of the IL approach for the 
development of novel drug candidates considering not only physico-chemical aspects but 
also the pharmaceutical profile of the developed active pharmaceutical ingredients with 
IL properties. Considering the utilization of ILs as solvents of drugs or as part of drug 
delivery systems, it is anticipated that the discussion will be focused on the efficiency and 
toxicity of the systems and on their influence on the pharmacokinetics and 
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pharmacodynamics of the vehiculated drugs. It is also planned to debate the motivations 
for the pharmaceutical usage of ILs as well as their peculiar properties that launched them 
in this context. Currently, the pharmaceutical utilization of ILs is one of the most relevant 
applications of these solvents, with impact on the safety and effectiveness of the involved 
processes and with benefits in terms of pharmaceutical formulations and pharmacological 
activity. It is our belief that this chapter is adequate for the book in project and can 
greatly enhance its acceptance and interest by readers in distinct research areas. 
 
 
ABBREVIATIONS 
 
Ionic Liquid(s)      IL(s) 
Research and Development     R&D 
GlaxoSmithKlein      GSK 
Active pharmaceutical ingredient(s)    API(s) 
Ethylammonium nitrate     EtNH3 [NO3] 
1-butylpyridinium chloride-aluminum chloride  bmpy [Cl]-AlCl3 
Tetrafluoroborate      BF4 
Hexafluorophosphate     PF6 
Generally recognized as safe     GRAS 
Volatile organic solvent(s)     VOCs 
Food and Drug Administration    FDA 
1-butyl-3-methylimidazolium tetrafluoroborate  bmim [BF4] 
NSAID(s) non-steroidal anti-
inflammatory drug(s) 
Ring closing metathesis     RCM  
Triethylammonium acetate     TEAA 
Support ionic liquid phase     SILP 
1-butyl-3-methylimidazolium  
bis(trifluoromethylsulfonyl)imide    bmim [NTf2] 
n-propyl-2,3-dimethylimidazolium  
bis(trifluoromethylsulfonyl)amide    dmim [[NTf2] 
DPEN (R,R)-1,2 
diphenylethylenediamine 
1-hexyl-3-methylimidazolium tetrafluoroborate  hmim [BF4] 
1-ethyl-3-methylimidazolium tetrafluoroborate  emim [BF4] 
1-butyl-2,3-dimethylimidazolium hexafluorophosphate  dbmim [PF6] 
1-ethyl-3-methylimidazolium chloride-aluminum chloride emim [Cl]-AlCl3 
1-butyl-3-methylimidazolium chloride-iron chloride  bmim [Cl]-FeCl3 
1-butyl-3-methylimidazolium chloride-aluminum chloride bmim [Cl]-AlCl3 
1-butyl-3-methylimidazolium chloride-zinc chloride  bmim [Cl]-ZnCl2 
1-ethylpyridinium tetrafluoroborate-zinc chloride  etpy [BF4]-ZnCl2 
1-butyl-3-methylimidazolium hexafluorophosphate  bmim [PF6] 
1-ethyl-3-methylimidazolium  
bis(trifluoromethylsulfonyl)imide    emim [NTf2] 
methyltrioctylammonium bis(trifluoromethylsulfonyl)imide moma [NTf2] 
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1-butyl-1-methylpyrrolidinium  
bis(trifluoromethylsulfonyl)imide    bmpyr [NTf2] 
1-hexyl-1-methylpyrrolidinium  
bis(trifluoromethylsulfonyl)imide    hmpyr [NTf2] 
methyl tert-butyl ether     MTBE 
1-methylimidazolium acetate     mim [OAc] 
1-methoxyethyl-3-methylimidazolium methanesulfonate moemim [Ms] 
1-methoxyethyl-3-methylimidazolium trifluoroacetate  moemim [TFa] 
1-butyl-3-methylimidazolium trifluoroacetate   bmim [TFa] 
1-butyl-3-methylimidazolium methanesulfonate  bmim [Ms] 
1-butyl-3-methylimidazolium hydroxide   bmim [OH] 
dimethylimidazolium dimethylphosphate   dmim [(CH3O)2PO2] 
1-hexyl-3-methylimidazolium acetate    hmim [OAc] 
1-ethyl-3-methylimidazolium acetate    emim [OAc] 
1-methylimidazolium hydrogen sulfate   hmim [SO4] 
1-butylimidazolium tetrafluoroborate    hbim [BF4] 
1-hexyl-3-methylimidazolium hexafluorophosphate  hmim [PF6] 
1-octyl-3methylimidazolium hexafluorophosphate  omim [PF6] 
1-ethyl-3-methylimidazolium methanesulfonate  emim [Ms] 
1-ethyl-3-methylimidazolium trifluoromethanesulfonate emim [TfMs] 
dimethylimidazolium dimethylphosphate   dmim [(CH3O)2PO2] 
1-hexyl-3-methylimidazolium chloride   hmim [Cl] 
1-tetradecyl-3-methylimidazolium bromide   tmim [Br] 
1-hexyl-3-methylimidazolium bromide   hmim [Br] 
Ionic liquid(s) with pharmaceutical activity   IL-API(s) 
 
 
1. INTRODUCTION 
 
The pharmaceutical industry faces nowadays unprecedented challenges and amendments. 
Drug development became a question of millions of dollars and the emergence of generic 
drugs led to dramatic decreases on the sales of huge market successes [1]. With this, the 
investment on research and development (R&D) tends to decelerate since the risks associated 
with drug discovery seem to not be in accordance with the current economic demands. It is 
known that 95% of the experimental drugs that reach clinical trials fail to be both effective 
and safe. Before this, 40% of the novel drug candidates never reach this stage due to poor 
pharmaceutical properties such as reduced solubility or diminished permeation of the blood-
brain barrier [2].  
Additionally, the demands regarding the environmental impact of drug discovery are on 
the frontline of the guidelines of Green Chemistry [3]. 
In this scenario, the pharmaceutical industry has been struggling to keep the high 
standards of R&D whit the demands of preserving economically viability and integrate 
environmental sustainability. Novel approaches and management models have been 
implemented and at the same time the academic community started to invest on innovative 
pathways for the development and synthesis of novel drug candidates. Additionally, there has 
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been also investment on the reformulation of old synthetic and production processes to make 
them more adequate to the current economic and environmental demands. Some 
pharmaceutical companies are nowadays sensitive to this matter and are aware of the 
environmental consciousness of the general population. Companies like Pfizer and 
GlaxoSmithKlein (GSK) created internal guidelines (in accordance with the Green Chemistry 
principles) that aim, among others, the reduction of greenhouse emissions, the minimization 
of the impact of R&D (from drug discovery to usage and disposal) and the sustainable 
utilization of water. On the chemical perspective, one of the most obvious and intuitive 
approach is the search for greener alternative solvents in research, development, and 
manufacturing of novel active pharmaceutical ingredients (APIs) [4]. 
In this context, ionic liquids (ILs) emerged as a new class of compounds with properties 
that empower their pharmaceutical application in a variety of strands. In April 2000, industry 
and academia joined efforts and ideas on a NATO Advanced Research Workshop on the topic 
of “Green Industrial Applications of Ionic Liquids” opening interesting perspectives 
regarding the future utilization of these compounds.  
Even though the industrial applications in this field are still scarce, the peculiar properties 
of ILs envision immense and successful possibilities illustrated by an increasing number of 
literature examples [5]. ILs are being explored as solvents or reagents in a variety of 
pharmaceutical processes and as reaction media for common synthetic routes of both known 
and novel drugs [6]. Additionally, ILs can be part of distinct drug delivery systems for drugs 
with reduced bioavailability [7-10].  
Ultimately, the biological activity of ILs can be explored to form active pharmaceutical 
ingredients (APIs) with tunable physico-chemical and biological properties [11-14]. Still, 
changes at the industrial level demand a strict and rigid protocol in order to guarantee the 
safety and viability of the developed drugs. 
 
 
Figure 1. Current demands of the pharmaceutical industry. 
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Figure 2. Pharmaceutical applications of ILs. 
So, aspects like pharmaceutical profile, safety and human toxicity, environmental impact 
and biodegradability must be deeply addressed and explored to promote the acceptance of ILs 
by pharmaceutical industry. 
The following discussion will be focused on the evolution of the IL concept to justify the 
pharmaceutical potential of these solvents. The main features and advantages of the 
abovementioned pharmaceutical possibilities will be emphasized and where possible, 
literature and industrial examples will be explored and debated.  
 
 
2. HISTORICAL PERSPECTIVE OF ILS 
 
Most documents focused of the history of ILs go back to the 19th century, to the “red oil” 
obtained from Friedel-Crafts reactions and to 1914 where the first IL of history, 
ethylammonium nitrate (EtNH3 [NO3]), was synthesized [15]. However, ILs as we know 
them today can find their origin in the 1960´s when U.S Air Force Academy started a project 
based on the replacement of LiCl-KCl molten salt electrolyte in thermal batteries [6]. By that 
time, the involved researchers managed to synthesize and characterize a totally ionic, non-
aqueous solvent, 1-butylpyridinium chloride-aluminum chloride (bmpy [Cl]-AlCl3), an alkyl-
chloroaluminate that triggered the interest of chemists on ILs, especially those on the 
electrochemistry field. This was the first compound fitting the definition of IL that has been 
accepted for almost a century since Waldens´ studies in 1914: a salt which melts at or below 
100ºC.  
This IL constitutes the first element of the so called first generation of ILs that was 
mainly composed of dialkylimidazolium and alkylpyridinium cation derivatives combined 
with chloroaluminate and other metal halides anions. These compounds were largely studied 
by Osteryoung group [16, 17] and other researchers for their tunable and unique physical 
properties such as density, viscosity and thermal stability, among others. However, the 
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majority of these compounds are liquid only on a very narrow composition range and demand 
particular conditions of handling since chloroaluminates are water and oxygen sensitive. 
Additionally, the typical cations are very prone to reduction. Thus, these ILs are not suitable 
to be applied in biotransformations and not surprisingly the investigations on this field 
advanced to the synthesis of air and water stable compounds with wider liquid range. This 
was achieved initially through the combination of alkylimidazolium cations (less predisposed 
to reduction than the pyridinium ones) with water–stable anions like tetrafluoroborate (BF4), 
hexafluorophosphate (PF6) and acetate, among many others. These ILs gathered wide 
attention from the scientific community not only because of their low reactivity with water 
but also because of their large electrochemical window. These properties enabled the 
synthesis of novel ILs with tunable chemical properties combined with selected physical 
properties and that could be used as materials for diverse applications. These compounds 
constitute the second generation of ILs and are known for their lower melting points, 
negligible vapor pressure and moderate polarity. The boost on ILs research occurred between 
1999 and 2000 after the emergence of this second generation, with an exponential increase of 
applications in a variety of fields from biocatalysis to nanotechnology. The major drawback 
of these ILs is still their toxicity that even though can be modulated is inherent to the majority 
of the compounds and can be similar to that of chlorinated and aromatic solvents.  
As expected, the investigations followed the route to non-toxicity. This conducted to the 
utilization of stable, safe and biodegradable ions sometimes with biological activity and 
derived from materials generally recognized as safe (GRAS). The third generation of ILs is 
then composed of ILs with tunable chemical and physical properties and with reduced 
toxicity, like for instance ILs based on amino acids. Considering these particularities it is not 
unexpected that this new generation of ILs broadened the applicability of these compounds 
and triggered the investigation of their biotechnological and pharmaceutical potential. In this 
historical perspective it is important to highlight that even though the biological and 
pharmaceutical properties of ILs were explored before, namely through the investigation of 
antimicrobial, antifungal and anti-cancer activities of imidazolium, ammonium and 
phosphonium ILs [18-21], only at this stage this property was explored on purpose and 
recurring to selected materials.  
 
 
Figure 3. Historical perspective of the evolution of ILs according to their properties and applications. 
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3. APPLICABILITY OF ILS IN THE PHARMACEUTICAL FIELD 
 
As stated before, the peculiar properties of ILs make them suitable for distinct 
pharmaceutical applications and only their toxicity has hindered major developments in 
earlier years. Still, there are several situations in which toxicity can be modulated and others 
where toxicity can be a desirable property. With the forthcoming of the 3rd generation of ILs 
novel possibilities arose. 
This chapter will focus on the major possible applications of ILs in the pharmaceutical 
perspective: reaction media for the synthesis of APIs, as vehicles of drugs (solvents and drug 
delivery) and as APIs themselves. 
 
 
3.1. Synthesis of Pharmaceutical Drugs in IL Media 
 
In the pharmaceutical industry the use of volatile organic solvents (VOCs) is common 
and most of the times these solvents are an important part of the whole process from synthesis 
of APIs (or intermediates) to manufacturing operations like granulation and extraction [22, 
23].  
Considering that solvent use is about 80-90% of mass utilization in a typical 
pharmaceutical industry, the use of VOCs becomes a serious concern either from the human 
or environmental perspective as the toxicity of the production process is largely dependent on 
the nature of the selected solvents [24]. Moreover, the final formulations will unavoidably 
contain residual amounts of solvent. Even though there are strict rules and residual solvents 
limits improved by Food and Drug Administration (FDA) and other organizations and 
Pharmacopoeias, the risks and adverse effects of VOCs on human health are well known [25, 
26]. It is then desirable that novel approaches could be implemented, as it has been already 
stated on the introduction section. 
The current concerns of both academia and industry resulted already on several attempts 
to substitute VOCs by ILs in drug´s synthetic procedures [27, 28]. This approach is based on 
the demonstrated ability of ILs to drastically change the rate and selectivity of organic 
chemical reactions [6]. Currently, it is demonstrated that behind the environmental and safety 
issues, ILs can have also impact on the reactivity of the species involved in organic synthesis 
due to a fine balance of entropic and enthalpic contributions that involve the interactions 
inside the IL and between the ions and dissolved species. In fact, ILs can interact with solutes 
through dipolar and dispersion forces and act as strong hydrogen-bond acceptors [6]. The 
most important properties that set ILs apart from other solvents include: 
 
− existing as molten salts, in many cases even below room temperature 
− highly polar  
− negligable vapor pressure 
− nonflammable 
− wide liquid range (typically > 300 °C grade) 
− electrically conducting 
− noteworthy dissolution properties (of both organic and inorganic compounds) 
− high thermostability. 
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Table 1. Synthesized compounds with pharmaceutical interest through the 
implementation of organic reaction in IL 
 
 
Synthesized Compound Biological activity Reaction Ionic Liquid Ref 
Isoxazoline derivatives Antimicrobial Diels-Alder bmim [BF4] [32] 
Pyrrole-fused polycyclic 
heterocycles (alkaloyds) 
Alkaloids Diels-Alder bmim [BF4] [33] 
Pyrano/Thiopyrano fused 
polycyclic heterocycles 
Bactericide Diels-Alder TEAA [34] 
Regioselective arylated 
products 
Pharmaceutical 
intermediates 
Palladium catalyzed  bmim [PF6] 
bmim [BF4] 
[35] 
Arylboronates Pharmaceutical 
intermediates 
Anti-tumoral 
Palladium catalyzed bmim [PF6] 
bmim [BF4] 
hmim [BF4] 
emim [BF4] 
[30] 
(S)-Naproxen NSAID RCM bmim [BF4] [36] 
Hydrogenated aromatic 
ketones 
Pharmaceutical 
intermediates 
RCM Imidazolium ILs [37] 
Pravadoline NSAID Friedel-Crafts Imidazolium  
(PF6 and 
chloroaluminate) 
catalysts 
[38] 
Substituted indoles Pharmaceutical 
intermediates 
Friedel-Crafts Imidazolium 
chloroaluminate catalysts 
[39] 
Benzophenone derivatives Pharmaceutical 
intermediates 
Sunscreens 
components 
Friedel-Crafts Imidazolium 
chloroaluminate catalysts 
[40] 
Benzophenone derivatives Pharmaceutical 
intermediates 
Sunscreens 
components 
Friedel-Crafts Imidazolium 
chloroindate(III) 
catalysts 
[41] 
Coenzyme Q10 Antioxidant Friedel-Crafts Pyridinium 
chloroaluminate catalysts 
[42] 
Kinetic resolution of 
ibuprofen 
NSAID Biocatalysis 
(Candida rugosa lipase) 
bmim [PF6] 
bmim [BF4] 
bmim [MeSO4] 
mmim [MeSO4] 
bmim [OctylSO4] 
(C6H13)3C14H29PN3 
(C4H9)3CH3PTOs 
[43] 
Kinetic resolution of 
ibuprofen  
NSAID Biocatalysis  
(lipases fromAspergillus niger 
AC-54, Candida antarctica, 
Candida rugosa, Rhizomucor 
miehei and Thermomyces 
lanuginose  
bmim [PF6] 
bmim [BF4] 
[44] 
Caffeic acid phenethyl 
ester analogues 
Anti-tumoral Biocatalysis (Candida 
antarctica lipase) 
bmim [NTf2] [45] 
(R)-1-(4-
chlorophenyl)ethanol 
Pharmaceutical 
intermediate 
Whole cell biocatalysis 
(Lactobacillus kefir) 
bmim [PF6] 
bmim [NTf2] 
moma [NTf2] 
[46] 
(R)-1-(4-
chlorophenyl)ethanol 
Pharmaceutical 
intermediate 
Escherichia coli Saccharomyces 
cerevisiae 
bmim [PF6] 
bmim [NTf2] 
moma [NTf2] 
hmim [PF6] 
hmim [NTf2] 
[47, 48] 
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Synthesized Compound Biological activity Reaction Ionic Liquid Ref 
bmpyr [NTf2] 
hmpyr [NTf2] 
Chiral alcohols Pharmaceutical 
intermediate 
 [PF6], [NTf2] and [FAP] 
based hydrophobic ILs 
[49] 
(S)-3-chloro-1-phenyl-1-
propanol 
Pharmaceutical 
intermediate 
E. coli bmim [PF6]  
bmim [NTf2] 
emim [BF4] 
mmim [MeSO4] 
[50] 
Nucleosides derivatives Pharmaceutical 
intermediates 
 momim [Ms] 
momim [TFa] 
bmim [TFa] 
bmim [Ms] 
[51, 52] 
[53, 54] 
2,3-Disubstituted-1,3-
thiazolinin-4-one 
derivatives 
Antiparasitic Three component condensation 
(aldehyde, amine and 
mercaptoacetic acid) 
bmim [BF4] 
bmim [PF6] 
[55] 
2-Aryl-4,5-diphenyl 
imidazoles, pyrazole 
derivatives, oximes 
Pharmaceutical 
intermediates 
Sonochemical organic synthesis bmim [OH] 
emim [OAc] 
hmim [SO4] 
[56-58] 
Quinoline derivatives  Sonochemical organic synthesis hbmim [BF4] [59] 
 
The possibility of developing tailor-made ILs for particular purposes offers exciting 
opportunities in the organic chemistry field enabling the creation of tasks specific 
compounds. Moreover, ILs can often form biphasic systems with classic VOCs which allows 
the simple isolation of reaction products by extraction of the ionic liquid layer. Their ionic 
nature enables immobilisation and recycling of many transition metal catalysts.  
Many organic reactions have been studied in IL media sometimes with remarkable results 
[6, 29]. In a small number of cases the registered differences were small, not meeting 
anticipated high expectations or justifying extra expense. Herein we intend to focus on 
chemical reactions that can have significant utility at the pharmaceutical level and that in 
fundamental literature studies are not always immediately linked to that type of application. 
The selected reactions were: Dies-Alder, transition metal catalysed (including Heck reaction 
and ring-closing metathesis), Friedel-Crafts reactions not forgetting enzyme catalysed 
synthesis. Some examples of successful attempts to perform synthesis of APIs in ILs will be 
presented and discussed.  
The abovementioned reactions have been extensively studied in IL media [6, 27, 29-31]. 
Considering that nowadays drug synthesis can be based on the concept of convergent 
synthesis, according to which several fragments are prepared in parallel paths and combined 
at the end of the process, the informations collected from those reactions if not totally 
adequate to a whole synthesis process can be important in one of those parallel paths.  
The most important achievements in this field are compiled in Table 1. 
 
3.1.1. Diels-Alder Reaction 
The Diels-Alders reaction is an organic chemical reaction, more specifically, a 
cycloaddition, between a conjugated diene and a substituted alkene to form a substituted 
cyclohexene system [60]. This reaction enables the synthesis of complex polycyclic 
molecules with adequate control of stereochemistry. Even though this type of reaction 
accounts for only 5 to 11 % of C-C bond-forming reactions performed under Good 
Manufacturing Practice in the pharmaceutical industry [61], it is largely explored by scientists 
in academic drug development and thus deserves a special attention on this chapter. Among 
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the most important drugs synthesized recurring to Diels-Alder cycloaddition reaction, it is 
important to highlight several types of vitamins, prostaglandins and steroids [60]. 
Generically, the Diels-Alder reaction applied to organic synthesis exhibits higher reaction 
rates in water than in organic solvents, but the need to work with moisture sensitive substrate 
hinders the industrial implementation of the reaction in aqueous media [27]. This explains the 
extensive investigation of this reaction in ILs as alternative reaction media [6, 27, 28]. From 
the available studies it is important to highlight that the majority of the tested ILs incorporate 
Lewis acidic anions and conduct to a general increase of both reactivity and selectivity of the 
studied reactions, in less drastic conditions [62-65]. Besides the advanced knowledge on 
Diels-Alder reaction in IL media with interest for drug development, it is also possible to find 
recent concrete examples of the synthesis of pharmaceutical drugs or intermediates in ILs 
[32-34].  
The synthesis of isoxazoline derivatives can be performed in 1-butyl-3-
methylimidazolium tetrafluoroborate (bmim [BF4]) with enhanced reaction rates, improved 
yields, and high selectivity. The IL can be recycled and reused without loss of reactivity or 
selectivity. The synthesized isoxazoline derivatives are precursors of peptides with activity 
against gram positive and gram negative organisms and can constitute the basis for the 
development of new broad spectrum antimicrobial agent [32]. The same IL was used for the 
synthesis of pyrrole-fused polycyclic heterocycles through intramolecular 1,3-dipolar 
cycloaddition with higher rates and yields than in conventional organic solvents [33]. Along 
with the reutilization of the IL, the reaction products can also be readily separated by 
extraction. The synthesized compounds are of great interest since they are chemically related 
with well-known alkaloids such as myrmicarin and polyavolensin offering promising 
perspectives regarding the synthetic approach to natural products. Triethylammonium acetate 
(TEAA) was applied as greener solvent on a domino reaction based on the Diels Alder 
approach for the synthesis of pyrano and thiopyrano fused heterocycles thiopyrano fused 
heterocycles with bactericide activity [34]. Higher yields and shorter reaction times were 
attained.  
 
Scheme 1. Synthesis of isoxazoline derivatives by Diels-Alder reaction in the presence of bmim [BF4] 
[32]. 
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3.1.2. Transition Metal Catalysed Reactions 
Transition metal catalysed reactions have been widely used for decades in the 
pharmaceutical industry for the synthesis of drugs or intermediates. Specifically, palladium 
catalyzed reactions, including Heck reaction, represented, in 2005, about 60% of the C-C 
bond forming reactions in medicinal chemistry [61]. This is partially explained by the fact 
that the implementation of convergent synthesis demands final coupling steps compatible 
with a wide variety of functional groups. The palladium technology is in accordance with 
these demands and at the same time avoids the excessive use of protective groups. However, 
in the pharmaceutical field, this technique poses problems associated with the contamination 
of the synthesized APIs with palladium, demanding specific removal strategies. This problem 
can be circumvented recurring to heterogeneous catalysis or removal strategies like 
nanofiltration or scavenging methods [66].  
In the group of transition metal catalysed organic reaction, the Heck reaction and ring 
closing metathesis (RCM) will be highlighted due to their importance and available 
information. The Heck reaction is a classic example of a palladium catalyzed carbon-carbon 
bond formation process recognized as a good method to attach olefins to (hetero)aromatic 
compounds [67, 68]. In normal reaction conditions, the Heck reaction is not totally 
regioselective and the palladium catalysts are not stable, leading to high catalyst consumption 
and difficulties in the implementation of the reaction. In this context, ILs were applied as 
solvents for the Heck reaction for the first time in 1996. There are several aspects that justify 
the massive application of ILs in metal catalysed organic reactions. Firstly, besides the 
environmental and safety issues, the use of a non-volatile solvent simplifies the work set-up 
for distillation and avoids the problems related to the formation of azeotropic mixtures, 
typical of VOCs. Additionally, metal catalysts are either soluble or can be immobilized in 
ILs. In the latter case, the resulting solution can be immobilized into a solid support resulting 
on a support ionic liquid phase (SILP) catalysts that combines the advantages of both 
homogeneous and heterogeneous catalysis making this approach very sensitive process 
technologies.  
Many researchers explored this strategy sometimes with slightly different approaches 
[68] providing important information for future developments in the pharmaceutical field. 
Also on the pharmaceutical field, palladium catalyzed reactions have been already 
implemented in IL media with positive results. The arylation of allylic alcohols by aryl 
bromides was comparatively studied in imidazolium ILs (1-butyl-3-methylimidazolium -
bmim [PF6], bmim [BF4] and 1-butyl-3-methylimidazolium bis(trifluoromethyl-
sulfonyl)imide bmim [NTf2]) and molecular solvents [35]. The regioselectivity of the reaction 
is highly affected by the nature of the solvent, with ILs being the best option for the formation 
of branched arylated products with the best β/α ratios reported till that time. Amongst the 
tested ILs, bmim [PF6] is the most favorable compound in terms of catalyst activity. This 
reaction conducts to the formation of substituted allylic alcohols with regiocontrol that 
constitute useful intermediates for pharmaceutical synthesis. The utilization of ILs overcomes 
deficient regioselectivity, the major problem of this kind of arylation. The synthesis of 
arylboronates by palladium catalyzed cross-coupling can be performed in alkylimidazolium 
ILs incorporating BF4 or PF6 anions [30]. Catalyst decomposition is however observed with 
ILs incorporating the PF6 anion as well as with emim [BF4]. From the tested ILs, bmim [BF4] 
and 1-hexyl-3-methylimidazolium tetrafluoroborate (hmim [BF4]) are the most appropriate 
solvents, with increased catalyst stability in the case of bmim [BF4]. Furthermore, with this IL 
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the reaction time is shorter than in conventional molecular solvents and the catalyst can be 
recycled from the IL. The synthesized boronate derivatives are important building blocks in 
organic synthesis and can present biological activity with applicability as anti-tumoral drugs 
[69]. Still in the field of transition metal catalyzed reactions, RCM is a ruthenium (Ru) 
catalyzed transformation that conducts to the formation of carbon–carbon double bonds [70]. 
This reaction belongs to the broad group of olefin metathesis and has gained popularity in the 
last decade since it enables the synthesis of functionalized heterocycles with applicability in 
several fields [71]. RCM has been widely explored for the synthesis of pharmaceutical 
compounds or intermediates such as azepine derivatives [72, 73], gambieric acid along with 
analogues [74] and acyclonucleoside phosphonates [75], among others. Considering the 
ability of ILs to stabilize metallic catalyst and the abovementioned advantages of transition 
metal catalyzed reaction in ILs, Ru mediated RCM soon started to be explored in this reaction 
media [6, 27, 76, 77]. Even though the initial applications of RCM in ILs revealed a 
beneficial effect of the tested compounds on the catalytic efficiency, they suffered from 
reduced stability of the catalyst, a behavior that was previously observed in molecular 
solvents [78]. The key step on the development of this strategy was the modification of the 
catalyst through functionalization with an imidazolium group [79, 80]. The obtained catalyst 
showed to be far more stable than the conventional ones with the additional possibility of 
being stored for several months. On a distinct perspective there are also reports on the 
combined use of ILs and VOCs [81] and on the study of RCM in imidazolium ILs under 
microwave irradiation [82].  
RCM in IL media has also been explored during the synthesis of compounds with 
pharmaceutical interest. (S)-Naproxen can be quantitatively obtained from the asymmetric 
hydrogenation of 2-arylacrylic acids catalyzed by a Ru catalyst immobilized in bmim [BF4] 
[36].
 
The enantioselectivities are similar or higher than those obtained with the homogeneous 
reaction. The catalyst can be recovered and reused without loss of catalytic activity or 
selectivity. A similar approach was adopted by Ngo and co-workers who managed to perform 
the asymmetric hydrogenation of aromatic ketones. In this case, polar bisphosphonic acid-
derived Ru catalysts were immobilized in imidazolium ILs [37] for the production of 
pharmaceutical intermediates free of metal contaminants. The catalytic performance is highly 
affected by the nature of the IL with n-propyl-2,3-dimethylimidazolium bis 
(trifluoromethylsulfonyl)amide (dmim [NTf2]) providing the best results in terms of catalyst 
efficiency, when compared to bmim [BF4] and bmim [PF6]. As before, both IL and 
immobilized catalyst can be recycled and reused without leaching of Ru into the organic 
compounds.  
 
0.1% Ru(IL)(DPEN)Cl2
2 mol% Kot Bu
IL = bmim [BF4]; bmim [PF6]; dmim [[NTf2]
DPEN = (R, R)-1,2-diphenylethylenediamine
O
R R1
+ H2
R R1
OH
 
Scheme 2. Asymmetric hydrogenation of chiral ketones catalyzed by Ru-IL catalysts [37]. 
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3.1.3. Friedel-Crafts Reaction 
The Friedel-Crafts acylation reaction represents a synthetic process of great interest to 
organic chemists of academia and industry being involved in the production of several 
pharmaceuticals. Since its first description in 1887, this reaction has been increasingly 
recognized as the method of choice to perform the alkylation of arenes and heteroarenes and 
form C-C and C-heteroatom bonds [83]. Even though the Friedel-Crafts reaction is 
traditionally catalyzed by Lewis acids, it is also possible to accelerate the reactions recurring 
to strong Brønsted-acids including sulfuric acid, hydrofluoric acid or super acids. More 
environmentally benign options involving alkylation by means of alcohols and styrenes were 
implemented recently as an alternative to alkyl chlorides. The environmental aspects are 
worsen by the large amounts of VOCs generally utilized in these reactions [84]. In this 
context, ILs soon started to be explored in this kind of reaction with interesting results [85]. 
The first application of an IL in a Friedel-Crafts reaction was accomplished in 1986 and 
involved the effective utilization of a mixture of 1,3-dialkylimidazolium chloride and 
aluminum chloride as catalyst [85]. The success of the application is explained by the strong 
Lewis acidity of acidic chloroaluminate ILs. Since then, it was found that the ILs provide also 
better alkylate quality than those obtained with conventional catalysts. There is a vast list of 
applications of IL-catalysts in diverse Friedel-Crafts reactions in a variety of fields, all of 
them confirming the adequacy of these solvents to the performed reactions [28, 83, 84, 86-
88].  
Due to the importance of the Friedel-Crafts reaction for the pharmaceutical industry it is 
not surprising that this reaction was studied in IL media for the production of compounds 
with pharmaceutical interest. The first report on the synthesis of a pharmaceutical drug was 
presented by Earle and co-workers [38]. Based on their past experience with Friedel-Crafts 
reaction of indoles, the researchers managed to synthesize pravadoline, through a 
combination of Friedel-Crafts reaction and a nucleophilic displacement reaction. In the 
presence of bmim [PF6], the alkylation of 2-methylindole with 1-(N-morpholino)-2-
chloroethane occurs at room temperature with a yield of 95%. The change of the IL to 1-
butyl-2,3-dimethylimidazolium hexafluorophosphate (dbmim [PF6]) leads to an increase of 
yield to 99%.  
It must be also highlighted that the production of acidic aqueous wastes is decreased due 
to the fact that the reaction, performed entirely in IL, does not require a Lewis acid catalyst 
reducing the acidity of the reaction with consequent reduction of wastes and by-products 
leading also to increased yields. Moreover, in the adopted scheme the product is easily 
separated and the solvent is recycled.  
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Scheme 3. Synthesis of pravadoline by the Friedel-Crafts reaction in IL media [38].  
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This reaction was also tested in 1-ethyl-3-methylimidazolium chloride-aluminum 
chloride (emim [Cl]-AlCl3), a chloroaluminate IL, with results similar to those obtained with 
a conventional Friedel-Crafts approach and yields between 40 and 89%, with the drawback of 
producing large amounts of acidic waste.  
This latter approach can also be explored for the production of substituted indoles by 
Friedel-Crafts acylation of indoles at room temperature [39]. The obtained products are 
indoles substituted at different positions with diverse functional groups that can be used as 
pharmacophore blocks for the synthesis of several molecules with pharmaceutical interest. 
Chloroaluminate ILs integrated also a broader study of Friedel-Crafts acylation for the 
synthesis of benzophenone derivatives recurring to distinct IL catalyst [40]. Amongst the 
tested ILs, 1-butyl-3-methylimidazolium chloride-iron chloride (bmim [Cl]-FeCl3), exhibited 
much higher catalytic activity than that registered for 1-butyl-3-methylimidazolium chloride-
aluminum chloride (bmim [Cl]-AlCl3), 1-butyl-3-methylimidazolium chloride-zinc chloride 
(bmim [Cl]-ZnCl2) and benzene. With this catalyst, reaction yields up to 97% were obtained 
with shorter reaction times. As before, it was possible to easily isolate the reaction products 
and the ILs could be recycled and reused with both economic and environmental advantages. 
As an alternative to the use of imidazolium based ILs, Chen and co-workers explored the 
potential of pyridinium ILs combined with AlCl3, ZnCl2, FeCl3, SnCl2, SnCl4 and CuCl for 
the synthesis of an intermediate of coenzyme Q10 by Friedel-Crafts alkylation under 
microwave irradiation [42]. Generally, the catalytic activity of the ILs enhanced with the 
increase of their Lewis acidity with 1-ethylpyridinium tetrafluoroborate-zinc chloride (etpy 
[BF4]-ZnCl2) showing the best catalytic activity, with a yield of 89% after 150 seconds of 
reaction. The method exhibits the same economical and safety advantages described for the 
abovementioned approaches. In an attempt to provide alternative pathways for this important 
reaction, Earle and co-workers proposed chloroindate(III) ILs as catalysts for Friedel-Crafts 
acylations for the production of benzophenone derivatives [41]. The study involved the 
comparison of the synthesis performance in several chloroindate ILs and 1,2-dichloroethane. 
It was demonstrated that the best yield was obtained when indium(III) chloride was combined 
with bmim [NTf2] either as a solution or as a binary IL (bmim [NTf2]-InCl3), with reaction 
yields between 75 and 96%. No catalytic activity was observed whit bmim [OTf] or bmim 
[BF4]. The importance and significance of the obtained results is only fully understood 
considering that the aromatic compounds used for the synthesis are usually non-reactive. This 
issue is overcome with this approach. 
 
3.1.4. Biocatalysis 
Even though nowadays stereoselectivity can be achieved through metal transition 
catalysis, biocatalysis still remains an important tool for the pharmaceutical industry on the 
search for stereoisomer drugs instead of racemates [89, 90]. Besides the issue of selectivity, 
some of the most important features of enzymes, as industrial catalysts, are related with their 
aptitude to accept a wide range of substrates, even artificial ones, and with their ability to 
operate in non-aqueous environments [6]. The use of enzymes in synthetic processes does not 
require the use of protective groups, even in complex molecules, with simplification of the 
process and reduction of the associated costs. Several industrial processes apply nowadays 
enzyme-catalyzed reactions for the large-scale production of APIs. As examples, Schering-
Plough synthesizes an azole antifungal agent in hundred-kilogram quantities and Bristol-
Myers Squibb pharmaceutical research group published a number of plant scale chemo-
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enzymatic synthesis performed in organic media. For years, the use of water as solvent in 
enzymatic reactions limited the field of application of enzymes in biocatalysis and the 
productivity of some processes, particularly those involving hydrophobic substrates [91]. As a 
consequence, the applicability of catalysis in non-aqueous solvents was implemented and 
discussed and as a result, new reaction media were suggested [92]. The possibility of working 
with hydrophobic substances, the decrease in microbial contamination and reduction of side 
reactions are the main advantages related with the development of procedures in non-aqueous 
media. Organic solvents helped to reduce some problems such as the insolubility of 
hydrophobic compounds and propagation of radicals in aqueous solutions offering benefits 
related with enzyme stability and selectivity [93, 94]. Due to the well-known drawbacks of 
VOCs, and reported inactivation phenomena, ILs emerged as an alternative for biocatalysis in 
the last decade. The applicability of ILs in biocatalysis was explored intensively through the 
study of an uncountable number of enzymes in huge variety of ILs with structural variability. 
The results of the majority of these studies are compiled and discussed in several reviews [95-
97].  
The research in this field indicates that biocatalytic reactions in ILs exhibit higher 
selectivity and faster rates with enhanced enzyme stability [98], making this association very 
promising for organic synthesis [90]. The relationship between ILs and enzymes has been 
discussed by many authors and the main explanations were pointed out. The polarity of ILs 
seems to be one of the most important factors affecting enzyme stability and selectivity. 
Indeed, polar solvents increase the solubility of polar substrates conducting to faster and more 
selective reactions [99]. Other studies reveal that the viscosity of ILs can also have a strong 
impact on enzyme´s activity [98]. High viscosity may produce a decrease in the rate of 
diffusion of the species involved in the process with reduction of the interaction of the 
enzyme with its substrate which can influence negatively the yield of reaction. 
The hydrogen bond capacity of ILs has been also considered very important for protein 
stability and maintenance of its native structure [100]. The classic enzyme thermal unfolding 
is prevented by the entrapment of enzymes, with small amounts of water, in the hydrogen 
bond network of ILs [101]. The suppression of side reactions due to the decrease of water in 
the reaction media has also been associated with the increased yield of enzymatic reactions in 
ILs [102].  
Even though the investigations in the field of biocatalysis in ILs began by the 
replacement of organic solvents, nowadays there are studies involving biphasic solvents in 
which water miscible IL are used in aqueous systems. Regarding biphasic systems, the 
possibility of enzyme reutilization has already been studied with success [102]. There is also 
the possibility of work in three phase systems in which ILs, organic solvents and water can be 
associated to modulate the solubility of substrates and enzyme activity [103].  
The first study describing an enzymatic reaction in ILs involved the use of a protease, 
thermolysin, for the synthesis of Z-aspartame, with similar reaction rates but higher enzyme 
stability than those obtained with traditional organic solvents [104]. After this, many works 
involving the use of proteases and lipases, among many others, in ILs have been developed, 
confirming the advantages of these solvents in biocatalysis [6, 105].  
In this context, ILs were soon considered interesting alternatives to VOCs on 
pharmaceutical synthesis and other bioprocess involving pharmaceutical drugs [106]. The 
kinetic resolution of ibuprofen catalyzed by Candida rugosa lipase in IL media is an excellent 
example of the successful combination of biocatalysis and ILs [43]. Chirality is a key issue 
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for ibuprofen due to the differences registered between S-(+)-ibuprofen and R-(-)-ibuprofen, 
with the latter being 100-160 times less active than the first one. For this study, the authors 
selected seven ILs with structural variability and compared the results with those obtained 
with isooctane. Bmim [PF6] improved both the kinetic resolution and the enantioselectivity 
with high enzyme stability. Studies of the time course conversion and enzyme stability as a 
function of time in both isooctane and bmim [PF6] confirmed that this IL is a valid alternative 
for the kinetic resolution of ibuprofen. Later on, several types of lipases (from Aspergillus 
niger AC-54, Candida antarctica, Candida rugosa, Rhizomucor miehei and Thermomyces 
lanuginose) were studied to perform the resolution of (RS)-ibuprofen in two-phase systems 
containing bmim [PF6] and bmim [BF4] [44]. It was noticed that C. rugosa lipase conducted 
to the best results in terms of conversion degree, enantiomeric excess of remaining acid and 
E-value in a two phase system composed of bmim [PF6] and isooctane. The influence of the 
IL was more pronounced on the E-value being less significant regarding the conversion 
degree. A similar tendency was observed with A. niger lipase. Acceptable results were also 
attained with C. antarctica lipase in terms of esterification activity and enantioselectivity. 
This enzyme can also be used for the synthesis of nucleoside drugs esters resorting to an IL as 
additive [107]. The lipase catalyzed transterification of ribavirin was performed in mixtures 
of acetone and increasing concentrations of imidazolium ILs (bmim [BF4], bmim [PF6] and 
emim [BF4]). The best results in terms of transterification extent were obtained with bmim 
[BF4] 10%, with an increase of the reaction rate of about 3.5 times when compared with the 
assay in the absence of IL. These observations were correlated to the increase of solubility of 
the nucleoside analogue due to the presence of the IL and to enzyme conformational changes. 
In the presence of bmim [BF4] the nucleoside synthesis was carried out with excellent 
regioselectivity, fast reaction rate and high yield.  
Resorting also to C. antarctica lipase, Kurata and co-workers performed the synthesis of 
caffeic acid phenethyl ester analogues, with antiproliferative effect on tumor cells, in bmim 
ILs with variable anions [45]. The transesterification reaction of methyl caffeate with various 
alcohols to produce the abovementioned analogues is favored in the presence of bmim [NTf2]. 
Considering the registered changes in activity, it was concluded that the activity of enzyme is 
anion dependent. The optimized synthetic system resulted on the production of 2-
cyclohexylethyl caffeate and 3-cyclohexylpropyl caffeate with conversion yields of 97.6 and 
93.8%, respectively. Both compounds exhibit antiproliferative activity higher than caffeic 
acid and comparable to 5-fluorouracil.  
In the field of biocatalysis, it is also important to highlight whole cell catalyzed processes 
which can present major advantages over the use of isolated enzymes [108]. In 
biotransformations involving more than one enzyme, the use of whole-cell biocatalysts 
(recombinant or not) is almost mandatory as it avoids costly and time consuming enzyme 
purification.  
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Scheme 4. Synthesis of caffeic acid phenethyl ester in IL media [45]. 
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In addition, the use of cofactors can be avoided and the process can benefit from the 
intracellular regeneration of cofactor when the membrane of the whole-cell biocatalyst 
remains stable during the catalytic route. This approach is generally very adequate to 
asymmetric synthesis due to low water solubility of substrates or products and inhibitory 
effects of the reactants on the biocatalyst. Considering the issue of membrane integrity, the 
selection of the solvent in whole cell biocatalysis is of the most importance and can enhance 
or highlight the mentioned advantages of this catalytic methodology. In this context, it has 
been demonstrated that ILs can be successfully employed in whole cell biocatalysis in 
replacement of VOCs [46-49, 108]. Most of the referred applications of whole cell 
biocatalysis in IL media have pharmaceutical interest. This approach has been mainly applied 
to the asymmetric synthesis of chiral alcohols [46-50] which are frequently employed as 
pharmaceutical intermediates [109]. Pfruender and co-workers demonstrated for the first time 
that a cellular cofactor regeneration system can be active in the presence of water-immiscible 
imidazolium and ammonium ILs (bmim [PF6], bmim [NTf2] and methyltrioctylammonium–
NTf2, moma [NTf2]) [46]. This important demonstration is a result of the study of the 
Lactobacillus kefir catalyzed asymmetric reduction of chloroacetone to (R)-1-(4-
chlorophenyl)ethanol in ILs, used as substrate reservoir and extracting agent. The results of 
the synthetic process were compared with those obtained with commonly used VOCs, like n-
octanol and methyl tert-butyl ether (MTBE). In the presence of bmim [NTf2] the chemical 
yield of the synthesis of the chiral alcohol can be doubled and the purity of the product is 
excellent. With the other tested ILs the results are very acceptable comparing with MTBE. It 
was also evidenced that the tested ILs do not affect L. kefir membrane integrity and can even 
enhance it, probably due to changes in morphology. Similar results were obtained in a study 
of the same process catalyzed by Escherichia coli and Saccharomyces cerevisiae [47, 48] 
confirming that the selected ILs can be applied on the whole cell biocatalyzed production of 
pharmaceutical chiral alcohols. A set of other commercially available ILs proved to be also 
good options for the asymmetric reduction of ketones using recombinant E. coli as biocatalyst 
[49, 110]. As before, the tested compounds do not affect negatively the intracellular 
regeneration of NADH nor cell membrane integrity. More recently, Choi and co-workers 
confirmed the adequacy of imidazolium ILs, with special focus on bmim [NTf2], for the 
production of chiral alcohols through the E. coli catalyzed synthesis of (S)-3-chloro-1-phenyl-
1-propanol, a chiral precursor of anti-depressant drugs [50]. 
 
3.1.5. Other Applications 
Nucleoside chemistry is one of the most important areas in pharmaceutical research 
providing compounds with wide application in cancer and viral chemotherapy. The problems 
associated with the insolubility of nucleoside derivatives have hindered the development of 
novel strategies and ILs soon started to be explored as reaction media for the solubilization 
and synthesis of these compounds [51-55, 111]. Uzagare et al. performed a deep study of the 
solubility of 2´-deoxyribonucleosides in several imidazolium ILs [51]. The IL 1-
methoxyethyl-3-methyl imidazolium methanesulfonate (moemim [Ms]) proved to be a better 
option for the solubilization of the nucleosides than any other IL or VOC. The acylation and 
peracylation of the 2´-deoxyribonucleosides can be performed in this IL with good isolation 
of the reaction product with yields between 89 and 95%. The same IL was used for the 
selective benzoylation of nucleosides using benzoyl cyanide [52]. Highly efficient 
benzoylations in mild reaction conditions (25ºC) are achieved with selective benzoylation of 
Paula C.A.G. Pinto and M. Lúcia M.F.S. Saraiva 18
sugar hydroxyl groups over amine groups and preferential production of O-benzoylated 
derivatives. The major drawback of this strategy is the formation of the highly toxic HCN, as 
reaction by-product. As an alternative, the authors studied the process in the presence of 1-
methoxyethyl-3-methylimidazolium trifluoroacetate (moemim [TFa]) which exhibits the 
ability to dissolve both deoxyribo- and ribonucleosides [111]. This IL is a good alternative for 
the selective benzoylation of nucleosides with high yields, under ambient conditions. These 
results were of the most importance for the development of three nucleoside based anti-viral 
drugs namely stavudine, brivudine and trifluridine in three ILs, moemim [Ms], moemim 
[TFa] and bmim [TFa] [53]. In all cases, the selected ILs showed better solvent properties 
than the commonly used VOCs like N,N-dimethylacetamide. Moreover, the amount of 
required solvent is reduced due to the high solubility of the synthesized compounds in the 
ILs. Higher reaction rates are attained with this strategy. The same ILs, with the addition of 
bmim [Ms], were also applied to the synthesis of antiviral 5-halouracil nucleosides which can 
be also used as building blocks for the synthesis of other antiviral drugs [54]. As in the 
abovementioned studies, ILs proved to be good reaction media for this synthesis and in this 
case could be recovered up to 4 cycles without loss of yield.  
Two imidazolium ILs were also selected as reaction media for the synthesis of 2,3-
disubstituted-1,3-thiazolinin-4-one derivatives with antiparasitic activity [55]. The synthesis 
yield is low at room temperature but by increasing the temperature up to 80 or 90ºC the 
reaction yield increases to 87 and 74% with bmim [PF6] and bmim [BF4], respectively. Tests 
performed with bmim [PF6] demonstrate that the IL can be recovered and efficiently reused. 
This section could not be completed if the works of Zang et al. on sonochemical organic 
synthesis in IL media were not mentioned. Several compounds including 2-aryl-4,5-diphenyl 
imidazoles [56], pyrazole derivatives [57] and oximes [58] with pharmaceutical interest. For 
the synthesis of these compounds, the authors combined bmim [OH] [58], emim [OAc] [56] 
or hmim [SO4] [57] with ultrasonic irradiation. In all the tested conditions, the reaction time 
was reduced and the synthesis occurred efficiently with high yields, under mild conditions. 
Similarly, Heravi managed to synthesize quinolines derivatives, with pharmacological 
activity, through the combination of hbim [BF4] and ultrasound, resorting to methanol as co-
solvent [59]. 
To finish this section, two applications with immense potential to be implemented in 
pharmaceutical synthesis must be highlighted due to their importance on the safety and 
therapeutics perspective. Firstly, the oxidation of ketones, largely applied to the synthesis of 
antibiotics and steroids, was already performed in IL media resorting to imidazolium ILs as 
an alternative to the commonly used dichloromethane, chloroform and acetonitrile [112]. The 
most promising ILs were bmim [BF4] and 1-methylimidazolium acetate (mim [OAc]) 
providing yields of lactone and ester synthesis between 65 and 95%.  
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Scheme 5. Condensation of ketones to produce quinolone derivatives in the presence of hbim [BF4] 
[59]. 
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Again, ILs could be recycled 3 times without loss of yield. Finally, we highlight the 
major importance of the work of Hwang and co-workers regarding the formation of amyloid 
from α-synuclein in IL media. There are a number of amyloid related diseases that largely 
depend on the development of novel therapeutic strategies based on amyloid formation. 
However, amyloid formation is usually a very slow process which hinders more effective 
developments on this field. In this work, a set of imidazolium ILs and one pyridinium IL were 
tested and in all cases the ILs acted as stimulators of amyloid formation with decrease of the 
lag time of the process. Amongst the tested compounds, emim [NTf2] is a stronger promoter 
when compared with other ILs.  
 
 
3.2. ILs as Drug Vehicles 
 
Solubility is one of the most important properties during drug development. It limits the 
concentration that a dosage form can incorporate and the rate at which the molecule dissolves 
from the solid form. It is then a key property for gastro-intestinal absorption of orally 
administered drugs. In fact, poor aqueous solubility of drugs is one of the major causes for 
low systemic exposure and, consequently, lack of in vivo activity [2, 113]. From the total 
amount of new chemical entities developed in the pharmaceutical industry, 40% fail to reach 
higher development levels due to solubility problems [114, 115]. The importance of solubility 
during drug development is illustrated by the Biopharmaceutics Classification System (BCS) 
which is basically a guide for the prediction of the intestinal drug absorption, provided by the 
U.S. FDA [116]. In this classification system, prediction relies in only two major parameters: 
solubility and intestinal permeability. In this context, it is not surprising that the search for 
novel strategies to increase the solubility of new drug candidates is one of the biggest 
concerns of both industry and academic researchers. Various techniques are used for the 
enhancement of the solubility of poorly soluble drugs which include physical and chemical 
modifications of drug and other methods like particle size reduction, crystal engineering, salt 
formation, solid dispersion, use of surfactant, complexation, among others. The selection of 
the strategy to be adopted is highly dependent on drug´s property, site of absorption, and 
characteristic of the dosage form [117].  
ILs are well-known for their solvation properties that make them able to dissolve a wide 
range of organic and inorganic compounds [118]. This property has been associated with the 
fact that ILs form a highly solvating and little coordinating media. Additionally, the short 
range repulsive interactions between anions and cations enhance the solvent power of ILs 
[119]. In the pharmaceutical field, it has been demonstrated that ILs are capable of dissolving 
several drugs that are insoluble or poorly soluble in water and in the solvents commonly used 
in these applications [8, 13, 51, 111, 120-126]. Additionally, their inherent tunability 
associated with the possibility of designing a specific IL for a specific application are major 
attractions of these compounds in this field. Generally, there is an increase of the solvency of 
ILs with the increase of the alkyl side chain of the cation [127].  
The studies with nucleoside derivatives of Kumar and co-workers illustrate the 
importance of solubility studies in a stage prior to synthesis [52, 53, 111]. As described in 
section 1.3.1.5, imidazolium ILs present better solvent properties for both deoxyribo- and 
ribonucleosides than the commonly used VOCs. These findings opened new perspectives 
regarding the synthesis of nucleoside derivatives in IL media.  
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The pioneering researches of Professor´s A.T. Florence group boosted the pharmaceutical 
utilization of ILs as solvents or drug reservoirs [121-123]. This application is mainly related 
with the ability of ILs to dissolve poorly water-soluble molecules drugs like albendazole and 
danazol [122], dexamethasone [121, 123], penicillin V, progesterone and dehydro-
epiandrosterone [123]. For instance, the solubility of albendazole increased more than 20,000 
times in hmim [PF6] and more than 10,000 in bmim [PF6]. The issue of IL´s water miscibility 
was also explored during this evaluation considering the preferential utilization of aqueous 
systems during drug´s formulation. The water miscibility of poorly water-miscible ILs, like 
bmim [PF6], can be enhanced through the addition of a more water miscible IL with higher 
effects for more hydrophilic ILs. The variation of danazol solubility is far more significant 
with very good results in the water miscible IL bmim [BF4]. Hexafluorophosphate ILs of the 
imidazolium group were tested as solvents and reservoirs of progesterone, 
dehydroepiandrosterone, dexamethasone, sucrose and penicillin V [123]. It should be 
highlighted that the solubility decreases with the increase of the alkyl chain length from bmim 
to omim. All the ILs are adequate for the entrapment and release of solubilized drugs. 
Distinctly, the same ILs were utilized to evaluate the release rate of solubilized hydrophilic 
and hydrophobic drugs by means of the passage of an electric current through the immiscible 
ILs [121]. The application of electric current to the ILs increases the release of both 
solubilized drugs with the highest variation being registered for omim [PF6]. Similarly, Smith 
et al. studied the solubility of ibuprofen and paracetamol in bmim [PF6] and hmim [PF6] at 
different temperatures. Even though both ILs are good solvents of both drugs, the solubilities 
are higher in hmim [PF6] than in bmim [PF6]. ILs with trifluoromethanesulfonate and NTf2 
anions were selected to dissolve isoniazide [124], N-acetyl-L-cysteine, coumarin and 4-
hydroxycoumarin [125]. Trifluoromethanesulfonate ILs are better solvents for isoniazide 
[124], N-acetyl-L-cysteine and 4-hydroxycoumarin than NTf2 ones [125]. The inverse was 
observed for coumarin [125]. The solubility of isoniazide was also studied in ammonium ILs, 
together with other antibiotic drug pyrazinecarboxamide [128]. Amongst the tested 
compounds, didecyldimethylammonium nitrate is the best solvent for both drugs with 
isoniazid exhibiting higher solubility than pyrazinecarboxamide in all the tested ILs. 
ILs can also be design to provide tunable and adequate hydrophilic-lipophilic balance to 
enhance water solubility of poorly soluble APIs [126]. This was evidenced recently on a 
study with amphotericin B and itraconazole, two complex, amphiphilic drugs with reduced 
water solubility. The selection of the anions and cations took in consideration not only the 
desired hydrophilic-lipophilic balance but also safety issues keeping in mind that they must 
be approved for consumption. Thus, acetate ILs based on short-chain fatty amines were 
synthesized (by choosing complementary functionality in one or both ions) and their 
effectiveness as solvents was evaluated. The adopted strategy proved to be a good option not 
only for the solubilization of drugs in the ILs but also to solubilize and maintain the drug in 
aqueous media.  
Also on the perspective of the use of ILs as solvents of pharmaceuticals, there are already 
informations on the influence on drug´s properties that determine their pharmaceutical profile 
and in vivo behavior [129]. These informations were gathered during the study of 
imidazolium ILs as solvents of nimesulide, a widely used NSAID with reduced water 
solubility. The binding of nimesulide to human serum albumin (HSA) as well as its 
interaction with micelles of hexadecylphosphocholine to calculate partition coefficients, were 
studied in the presence and in the absence of emim [Ms] and emim [TfMs] 1%. As in aqueous 
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media, in the presence of the selected ILs, nimesulide binds strongly to HSA by means of 
spontaneous interactions. The studied drug-IL systems exhibit properties that favor the 
interaction with biological membranes, evidenced by the high Kp values. Thus, there are good 
perspectives for the effective absorption and distribution in vivo. 
ILs can also be incorporated in IL-in-oil microemulsions to be used as carriers of poorly 
soluble drugs [7-10]. Microemulsions are self-assembled structures widely recognized as 
vehicles for encapsulation, stabilization, and delivery of pharmaceutical drugs [130]. They are 
thermodynamically stable colloidal dispersions formed by water and oil and stabilized by an 
interfacial film or surfactant. The initial report on this topic was elaborated by Professor´s 
Goto group and involved a four component system composed of dimethylimidazolium 
dimethylphosphate (dmim [(CH3O)2PO2]), isopropyl myristate, polyoxyethylene sorbitan 
(Tween-80) and sorbitan laurate (span-20) for the delivery of acyclovir [8, 9]. The IL was 
selected as the most adequate compound on solubility studies that were performed with seven 
imidazolium ILs. The increase of IL content on the micelle conducts to an increase of micelle 
volume and the incorporation of acyclovir results on a slight decrease of the mean diameter. 
The efficiency of the proposed delivery system was studied in vitro recurring to a porcine 
skin model using Franz-type diffusion cells. Skin permeability and the transdermal 
permeation of acyclovir increases when IL based microemulsions are used. The insertion of 
IL 4%wt in the microemulsion leads to a reduction of less than 20% in cell viability (human 
epidermal model LabCyteTM EPI-MODEL 12). With these pioneering studies, the authors 
confirmed the adequacy of these microemulsions to perform transdermal drug delivery. In 
continuation, the authors studied a set of imidazolium ILs as dispersed phase [7]. It was 
noticed that hydrophilic ILs with coordinating anions can be solubilized on the core of 
Tween-80/ span-20/ isopropyl myristate micelles and form stable microemulsion droplets 
more effectively. It is important to highlight that the solubility of the ILs in the 
microemulsion follow the same tendency as in water. The potentialities of the delivery system 
were further explored with methotrexate and dantrolene, two poorly water soluble drugs. The 
solubility of both drugs is enhanced in microemulsions with dmim [(CH3O)2PO2] with further 
increase by higher IL concentration. Similarly, Dobler and co-workers prepared oil-in-water 
and water-in-oil microemulsions containing hmim [Cl] and bmim [PF6] and evaluated the 
influence of the ILs on the properties of the micellar systems [131]. The ILs can be 
successfully incorporated in the micelles and due to their antimicrobial activity can have the 
effect of a preservative. As related above, skin permeation is enhanced in the presence of ILs.  
Other microemulsion systems were explored as vehicles of insoluble drugs such as 
curcumin [132], dopamine and acetylcholine [133]. The hydrophilic IL bmim [BF4] increases 
about 7 times the association of curcumin with CTAB and induces a decrease of association 
in the case of cationic surfactants like sodium dodecylsulfate (SDS), acting like a modulator 
of drug´s solubilization in micellar systems. On a distinct perspective, the micellization and 
surface behavior of 1-tetradecyl-3-methylimidazolium bromide (tmim [Br]) was studied in the 
presence of dopamine and acetylcholine aiming the evaluation of the applicability of the 
micellar system in drug delivery [133]. The selected IL exhibits better surface activity and 
better drug carrier performance than the structurally similar cationic surfactant, 
tetradecyltrimethylammonium bromide. Imidazolium ILs are also good solvents for the 
release of APIs from styrene-divinylbenzene polymeric vehicles as demonstrated by Ramos-
Rodriguez and co-workers [127]. The studies conducting to this conclusion were based on 
atomistic and mesoscopic simulations that evaluated solubility parameters and the diffusion 
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of albendazole from the polymeric vehicle to an aqueous medium modified with bmim [BF4], 
bmim [PF6] or hmim [Br]. The diffusion of albendazole was related with the solvent power of 
the studied ILs, with bmim [PF6] inducing higher release from the vehicle than bmim [BF4] or 
hmim [Br] due to the higher polarity of [PF6]. The evolution of the research on this field has 
been only foreclosed by one of the most delicate issues that concerns with ILs: toxicity. 
Further developments on the use of ILs as carriers or solvents of drugs are largely dependent 
on the preparation of safer ILs with reliable toxicity data that could be readily accepted as 
GRAS and used as excipients in pharmaceutical formulations. 
 
 
3.3. ILs as Active Pharmaceutical Ingredients 
 
Despite the technological advances of the last decades, nowadays there is still a 
significant rate of failure during drug development in the pharmaceutical industry. A study 
conducted between 1990 and 2002 revealed that only 40% of the drugs that pass phase I and 
II clinical trials will reach the market [134]. Failure was associated with lack of efficacy 
(50%), safety concerns (30%) or both (20%). The issue of efficacy is quite intriguing 
considering that this is the major concern of phase II clinical trials. Drug´s efficacy is tightly 
associated with bioavailability that in turns is dependent on fundamental properties such as 
solubility, dissolution rate and lipophilicity. Besides economical and judgmental 
reformulations, the strongest possibilities to overcome this failure rates are to profile drug-
like properties as early as possible and work on lower-risk compounds. 
Typically, the pharmaceutical industry is based on solid and crystalline forms of APIs 
with claimed advantages in terms of purity, solubility and thermal stability [135, 136]. It is 
also commonly accepted that solid forms of APIs facilitate isolation, manufacturing and 
product handling with reduction of the costs of the overall production process. This tendency 
is further encouraged by a vast amount of guidelines, most of them provided by FDA, 
concerning the manufacturing and quality control of solid pharmaceuticals with a notorious 
lack of guiding principles for liquid dosage forms. However, solid forms of APIs often suffer 
from low solubility and polymorphic conversion which can influence negatively the 
bioavailability of the drug and ultimately its therapeutic effect [136]. 
Polymorphism is the ability of a compound to exist as two or more crystalline phases that 
exhibit distinct arrangements and/or conformations of the molecule in the crystal lattice [135, 
137, 138]. Thus, polymorphs display different physical, thermodynamic, spectroscopic, 
interfacial and mechanical properties. Moreover, the different lattice energies of polymorphs 
can originate different solubilities and dissolution rates, affecting the bioavailability of 
pharmaceutical drugs. Polymorphism is one of the major concerns of the pharmaceutical 
industry during drug development due its impact during formulation and on pharmacological 
effect, as the conversion can occur throughout drug manufacturing or storage [138]. During 
drug development, if polymorphs are detected the most active and stable is selected. As 
examples, acetaminophen (paracetamol) can be presented in two forms with distinct 
compression properties [137] and the antiviral drug ritonavir has an inactive polymorph that 
exhibits the ability to inactive the active polymorph [139]. Ranitidine hydrochloride has been 
subject of deep discussion and legal litigation due to an attempt to approve a more active 
polymorph than the patented and commercialized by GSK. However and despite all the 
concerns on this topic, problems with commercialized drugs can still occur. 
Ionic Liquids: A Pharmaceutical Perspective 23
Particle size is another problem related to solid forms of pharmaceuticals, so that there 
are rigid guidelines concerning this aspect. It is known that particle size influences several 
parameters that determine drugs´ bioavailability and stability [140]. 
In this context one cannot also forget the problems of solubility of the majority of the 
novel drug candidates that hinder their future commercialization [113]. It is then important to 
control critically polymorphism, solubility and particle size during the development of solid 
APIs to avoid failures in posterior phases.  
 
3.3.1. Control and Modulation of Physico-Chemical and Biological Properties  
of Pharmaceutically Active ILs 
The most common strategy of the pharmaceutical industry to overcome inadequate 
physico-chemical properties is salt formation [13, 135, 136]. Recent estimations indicate that 
around 50% of all drugs utilized in the pharmaceutical industry are salts with improved 
properties regarding the corresponding neutral molecules. As for neutral drugs, FDA has got 
lists of approved conterions which include organic and inorganic ones. Even though this 
strategy hinders some of the abovementioned problems, the possible combinations are 
relatively small and the industry recurs systematically to the same ions.  
In this context, an IL approach, in the design of novel APIs, appears to be appropriate as 
it enables uncountable possible cation-anion combinations while providing distinctive 
properties unreachable in solid salts namely enhanced solubility and absence of polymorphic 
forms [12, 14, 141]. In this pharmaceutically active ILs (IL-APIs), the cation and the anion 
can both present biological activity or the counterion can have the ability to reduce the 
adverse effects of the active ingredient or change its solubility, for example. The possibility of 
combining more than two ions in the same compound cannot be forgotten as it can provide an 
additional biological activity or property. In these cases, the total charge of the cations is 
balanced by the total charge of the anions [142, 143]. Even though not predictable, synergistic 
or additive effects must also be considered as they may provide novel treatment possibilities 
and distinct drug delivery options. Furthermore, the assertive combination of appropriate 
anions and cations empowers the chemical manipulation of the compounds with specific 
objectives related with the manufacturing process, the stability of the formulations, their 
bioavailability and eventual adverse effects. In this perspective, it is important to highlight 
that small modification of an API can result on dramatic changes of its properties and 
eventually on its classification in the BCS. Thus, the IL approach can be profitable not only 
from the technological perspective but also on the pharmacological point of view since the 
possibility of modulate the abovementioned properties can facilitate the interaction of the 
compounds with biological membranes with consequent increase in their bioavailability and 
higher probabilities to actuate in vivo.  
 
3.3.2. Synthesis and Profiling of Active Pharmaceutical Ingredients with IL Properties 
The synthesis of APIs with IL properties is based on the evident similarity between IL-
forming cations and APIs and on the assumption that the majority of bioactive ions present 
properties to form low melting salts, namely adequate size, diffuse charge and asymmetry. 
The initial developments on this field demanded a deep knowledge not only of the biological 
action of the ions but also of their ability to form ILs. Even though a critical ion selection is 
not a guarantee for IL formation, the most determining aspect during IL-APIs´ synthesis is 
Paula C.A.G. Pinto and M. Lúcia M.F.S. Saraiva 24
definitely ion selection. Independently from the objective, the ions must be GRAS 
compounds with properties to be incorporated in pharmaceutical formulations either as APIs 
or excipients.  
At this point, it is notorious that the research in this field is still mainly focused on the 
synthesis of novel compounds through the association of ions of distinct pharmacological 
groups or with diverse excipient properties. This is related with the relatively easy 
implementation of synthetic procedures based on metathesis reactions after the selection of 
ions with pharmaceutical interest. Moreover, the intensive investment on novel APIs with IL 
properties is still motivated by the enthusiasm related with the possibility of associating ions 
with the objective of modulate the pharmacological activity and physico-chemical properties 
while obtaining dual activity compounds.  
The research group of Professor Rogers developed pioneer work regarding the synthesis 
and characterization of APIs with IL properties with a significant amount of papers and 
patents on this topic [12, 13, 141-147]. The first experiences on this field were reported on an 
interesting article exploring the so called third evolution of ILs [14]. Table 2 summarizes the 
most significant IL-APIs synthesized in the last years as well as their main properties and 
pharmacological activity.  
Ranitidine docusate, lidocaine docusate and didecyldimethylammonium ibuprofenate can 
be synthesized through simple metathesis reactions to overcome issues of polymorphism, 
solubility and bioactivity [14]. The compounds exhibit dual activity since they incorporate 
well-known and widely used pharmaceutical ions and counterions with emollient (docusate) 
or antibacterial properties (didecyldimethylammonium). The association of docusate to 
lidocaine results on a hydrophobic API with increased thermal stability and enhanced 
bioactivity from topical application, possibly due to a slower release profile and higher skin 
permeability associated to the presence of the emollient. The three IL-APIs present low 
surface tension and low contact angles due to weak cation-anion interactions [161]. 
The IL-API approach enables the synthesis of compounds based on specifically selected 
ions. For instance benzalkonium and didecyldimethylammonium can form a dual active IL by 
combination with ibuprofen with applicability for the treatment of inflammation caused by 
bacterial infections [12]. Benzalkonium can also be used to form ILs with anions with similar 
activity, such as sulfacetamide. The result is an IL-API with enhanced antibiotic activity that 
can potentially reduce bacterial resistance. Similarly acetylsalicylic acid and salicylic acid can 
be combined with antimicrobial (cetylpyridinium, benzethonium, benzalkonium and 
hexetidinium), analgesic (tramadolium), local anesthetic (lidocainium and procainium) and 
antiarrhythmic (procainiumamide) cations to obtain dual activity IL-APIs with advantages in 
terms of solubility and functionality [145]. These combinations result in low melting or liquid 
salts at room temperature. However, acetylsalicylate IL-APIs suffer from low stability and 
their therapeutic application can only be guarantee if moisture is rigorously controlled. From 
the selected combinations, salicylate IL-APIs incorporating antibacterial actions, such as 
benzalkonium salicylate and cetylpyridinium salicylate exhibit promising physical and 
chemical properties that foresee their utilization in antimicrobial applications. This was 
further confirmed through the study of protein binding affinity, partition coefficients and 
surfactant properties of benzalkonium salicylate, cetylpyridinium salicylate and emim 
salicylate [148].  
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Table 2. Pharmacological activity and main features of IL-APIs 
 
IL-API Anion Cation Pharmacological 
activity Main features Ref. 
Ranitidine 
docusate 
O
O
OH
O3
-S
OH
CH3
CH3
CH3
CH3
 
O
N
+
CH3
CH3
H
S
NH NH
NO2
CH3
 
Histamine H2 
receptor 
antagonist  
Emollient 
- Absence of 
polymorphs 
- Low surface 
tension 
- Low contact 
angles 
[14] 
 Lidocainium 
docusate 
O
O
OH
O3
-S
OH
CH3
CH3
CH3
CH3
 
CH3
NH
N+ CH3
CH3
HO
CH3
 
Local anesthetic 
Emollient 
- Higher skin 
permeation 
Didecyldimethyl-
ammonium 
ibuprofenate CH3
CH3
CH3
O
O-
 
N
+ CH3
CH3
n
nCH3
CH3
n=7
 
Antibacterial 
Anti-
inflammatory 
- Anion with 
primary biological 
activity 
Benzalkonium 
ibuprofenate 
CH3
CH3
CH3
O
O-
 
N+ n
CH3 CH3
CH3
 
Antibacterial 
Anti-
inflammatory 
- Appropriate to 
combat 
inflammation 
associated to 
bacterial infections 
[12]  
 
Didecyldimethyl-
ammonium 
ibuprofenate CH3
CH3
CH3
O
O-
 
N+
CH3
CH3
n
nCH3
CH3
n=7
 
Antibacterial 
Anti-
inflammatory 
- Appropriate to 
combat 
inflammation 
associated to 
bacterial infections 
Benzalkonium 
sulfacetamide 
O
O
OH
O3
-S
OH
CH3
CH3
 
N
+
n
CH3 CH3
CH3
 
Antibacterial 
Anti-acne 
- Reduction of 
bacterial resistance 
Cetylpyridinium 
salicylate 
O-
O
OH
 
N+
C16H33
 
Antibacterial 
Anti-
inflammatory  
- Improved 
solubility 
- Strong bind to 
HSA 
- High partition 
coefficient 
- Slightly toxic 
(aquatic toxicity) 
[145, 
148, 
149] 
Cetylpyridinium 
acetylsalicylate 
O-
O
O
CH3 O
 
N+
C16H33
 
Antibacterial 
Anti-
inflammatory  
- Water sensitive 
- Low stability [145] 
Benzethonium 
salicylate 
O-
O
OH
 
O
O
N+
CH3
CH3CH3
CH3CH3
 
Antibacterial 
Anti-
inflammatory  
- Improved 
solubility 
[145, 
149] 
Benzethonium 
acetylsalicylate 
O -
O
O
CH3 O
 
O
O
N+
CH3
CH3CH3
CH3CH3
 
Antibacterial 
Anti-
inflammatory  
- Water sensitive 
- Low stability [145]  
Benzalkonium 
salicylate 
O-
O
OH
 
N
+
n
CH3 CH3
CH3
 
Antibacterial 
Anti-
inflammatory  
- Improved 
solubility 
- Strong bind to 
HSA 
- High partition 
coefficient 
- Slightly toxic 
(aquatic toxicity) 
[145, 
148, 
149] 
Paula C.A.G. Pinto and M. Lúcia M.F.S. Saraiva 26
Table 2. (Continued) 
 
IL-API Anion Cation Pharmacological 
activity Main features Ref. 
Benzalkonium 
acetylsalicylate 
O-
O
O
CH3 O
 
N+ n
CH3 CH3
CH3
 
Antibacterial 
Anti-
inflammatory  
- Water sensitive 
- Low stability 
 
[145] 
Hexetidinium 
salicylate 
O-
O
OH
 
NN
NH3
+
CH3
CH3 CH3
CH3CH3
 
Antibacterial 
Anti-
inflammatory  
- Improved 
solubility 
Lidocainium 
salicylate 
O-
O
OH
 
CH3
CH3
NH
NH
+ CH3
O
CH3
 
Local anesthetic 
Anti-
inflammatory 
- Improved 
solubility 
Procainium 
salicylate 
O-
O
OH
 
NH2
O
NH
+
CH3
O
CH3
 
Local anesthetic 
Anti-
inflammatory 
- Improved 
solubility 
Procainamidium 
salicylate 
O-
O
OH
 
NH2
O
NH
+
CH3
O
CH3
 
Antiarrhythmic 
Anti-
inflammatory 
- Improved 
solubility 
Tramadolium 
salicylate 
O-
O
OH
 
OH
O
CH3
NH+
CH3
CH3
 
Analgesic 
Anti-
inflammatory 
- Improved 
solubility 
Tramadolium 
acetylsalicylate 
O -
O
O
CH3 O
 
OH
O
CH3
NH+
CH3
CH3
 
Analgesic 
Anti-
inflammatory 
- Water sensitive 
- Low stability 
Emim salicylate O-
O
OH
 
N
N+
CH3
CH3
 
Low antibacterial 
activity 
Anti-
inflammatory 
- Improved 
solubility 
- Strong bind to 
HSA 
- Higher partition 
coefficient 
- Practically 
harmless (aquatic 
toxicity) 
[145, 
148, 
149] 
Emim ampicillin NH2
NH
O
N
O
H S
CH3
O O
-
CH3
 
N
N+
CH3
CH3
 
Antibacterial 
 
- Improved 
solubility 
-Higher thermal 
stability 
Higher partition 
coefficient 
 
 
 
 
 
 
 
 
[150-
152] 
 
 
 
 
 
 
 
 
 
C2OHmim 
ampicillin NH2
NH
O
N
O
H S
CH3
O O
-
CH3
 
N
N+
CH3
OH
 
Antibacterial 
 
-Improved 
solubility 
-Higher thermal 
stability 
Higher partition 
coefficient 
Choline 
ampicillin NH2
NH
O
N
O
H S
CH3
O O
-
CH3
 
N+
CH3
CH3CH3
OH
 
Antibacterial 
 
- Low toxicity 
- Improved 
solubility 
-Higher thermal 
stability 
- Higher partition 
coefficient 
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IL-API Anion Cation Pharmacological 
activity Main features Ref. 
TEA ampicillin NH2
NH
O
N
O
H S
CH3
O O-
CH3
 
N+
CH3
CH3
CH3
CH3
 
Antibacterial 
 
- Improved 
solubility 
-Higher thermal 
stability 
- Higher partition 
coefficient 
 
 
 
 
 
 
[150-
152] 
 
Cetylpyridinium 
ampicillin NH2
NH
O
N
O
H S
CH3
O O-
CH3
 
N+
C16H33
 
Antibacterial 
 
-Higher thermal 
stability 
- Higher partition 
coefficient 
T3htdph 
ampicillin NH2
NH
O
N
O
H S
CH3
O O
-
CH3
 
P
+
C6H13
C6H13H13C6
C14H29
 
Antibacterial 
 
-Higher thermal 
stability 
- Higher partition 
coefficient 
Tetracycline 
docusate 
O
O
OH
O3
-S
OH
CH3
CH3
CH3
CH3
 
OH O OH O NH2
O
OH
CH3 H
HHOH
H H
NH+
CH3CH3
 
Antibacterial 
Emollient  
- Lower solubility 
- Higher partition 
coefficient 
[153] 
Benzethonium 
saccharinate 
N
-
O
S
OO
 
O
O
N+
CH3
CH3CH3
CH3CH3
 
Antibacterial 
- Crystalline solids 
with low melting 
points 
- Absence of 
polymorphs 
[154] 
Propantheline 
acesulfamate 
N-
S O
OCH3
O
O
 
O
OO
N
+
CH3
CH3
CH3
CH3CH3
 
Muscarinic 
acethylcoline 
receptor 
antagonist [154, 
155] Propantheline  
p-
toluenesulfonate CH3
S
O
O-
O
 
O
OO
N+
CH3
CH3
CH3
CH3CH3
 
Muscarinic 
acethylcoline 
receptor 
antagonist 
Lidocainium 
ibuprofenate 
CH3
CH3
CH3
O
O-
 
CH3
CH3
NH
NH+ CH3
O
CH3
 
Local anesthetic 
Anti-
inflammatory - API-SILPs 
- Fast release 
- Controlled 
solubility 
[146] Tetrabutylphos-
phonium 
ibuprofenate CH3
CH3
CH3
O
O-
 
P+
CH3
CH3
CH3
CH3
 
Antibacterial 
Anti-
inflammatory 
Tuaminoheptane 
benzoate O
-
O
 
CH3 CH3
NH3
+
 
Nasal 
decongestant 
Preservative 
- Solid or liquid 
and water soluble 
or insoluble 
depending on the 
ration 
[156] 
Amantadine 
benzoate O
-
O
 
NH3
+
 
Antiviral/antipar-
kinson 
Preservative 
-Higher solubility 
(but still poor 
water soluble) 
Tuaminoheptane 
salicylate 
O-
O
OH
 
CH3 CH3
NH3
+
 
Nasal 
decongestant 
Anti-
inflammatory 
Keratolytic 
- Water soluble or 
insoluble 
depending on the 
ratio 
Amantadine 
salicylate 
O-
O
OH
 
NH3
+
 
Antiviral/antipar-
kinson 
Anti-
inflammatory 
Keratolytic 
- Water insoluble 
2-Pyrrolidino- 
ethanol salicylate 
O-
O
OH
 
NH + OH
 
Anti-
inflammatory 
Keratolytic 
- Water soluble or 
insoluble 
depending on the 
ratio 
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Table 2. (Continued) 
 
IL-API Anion Cation Pharmacological 
activity Main features Ref. 
Tuaminoheptane 
gentisate 
O-
O
OH
OH
 
CH3 CH3
NH3
+
 
Nasal 
decongestant 
Analgesic 
- Solid 
- Water soluble 
 
Amantadine 
gentisate 
O-
O
OH
OH
 
NH3
+
 
Antiviral/antipar-
kinson 
Analgesic 
- Water insoluble 
2-Pyrrolidino-
ethanol gentisate 
O-
O
OH
OH
 
NH + OH
 
Analgesic - Higher solubility 
than gentisic acid 
Tuaminoheptane 
salicylate 
O-
O
OH
 
CH3 CH3
NH3
+
 
Nasal 
decongestant 
Anti-
inflammatory 
Keratolytic 
- Rapid membrane 
permeation [157] 
Bromohexinium 
ibuprofenate CH3
CH3
CH3
O
O-
 
N
CH3
NH3
+
Br
Br
 
Mucolytic 
Anti-
inflammatory 
Lidocainum 
etodolac NH O
CH3
CH3
O
O-
 
CH3
CH3
NH
NH+ CH3
O
CH3
 
Local anesthetic 
Anti-
inflmmatory 
- Higher skin 
permeability 
- Safe and well 
tolerated  
(results of clinical 
trials) 
[158-
160] 
Benzethonium 
docusate 
O
O
OH
O3
-S
OH
CH3
CH3
CH3
CH3
 
O
O
N
+
CH3
CH3CH3
CH3CH3
 
Antibacterial 
Emollient 
- Water insoluble 
- Moderately toxic 
(aquatic toxicity) 
[149] 
Benzethonium 
bistriflimide  
O
O
N+
CH3
CH3CH3
CH3CH3
 
Antibacterial 
- Water insoluble 
- Moderately toxic 
(aquatic toxicity) 
Trihexyltetradecyl-
phosphonium 
bistriflimide S
N-
S
O
O
F
F F
F
F
F
O
O
 
P
+
CH3
CH3
CH3
CH3
 
Antibacterial - Water insoluble 
Trihexyltetradecyl-
phosphonium 
docusate 
O
O
OH
O3
-
S
OH
CH3
CH3
CH3
CH3
P+
CH3
CH3
CH3
CH3
 
Antibacterial 
Emollient - Water insoluble 
Trihexyltetradecyl-
phosphonium 
salicylate 
O-
O
OH
 
P+
CH3
CH3
CH3
CH3
 
Antibacterial  
Anti-
inflammatory 
- Water insoluble 
 
The three compounds bind strongly and spontaneously to human serum albumin and 
exhibit the ability to form micelles. Moreover, the determined partition coefficients are up to 
6 times higher than for sodium salicylate. These features indicate that these IL-APIs can exert 
direct effect on cell membranes and present adequate properties to be incorporated in 
antimicrobial pharmaceutical formulations, mainly topical ones. 
Also in the field of antimicrobials, the thermal stability, solubility and melting point of 
ampicillin can be dramatically changed by association with organic cations such as emim, 1-
hydroxy-ethyl-3-methylimidazolium (C2OHmim), choline, tetraethylammonium (TEA), 
Ionic Liquids: A Pharmaceutical Perspective 29
cetylpyridinium and trihexyltetradecylphosphonium [150-152]. IL-APIs can be obtained 
through the neutralization of moderately basic ammonia solutions of ampicillin with the 
mentioned cations. The obtained compounds present more adequate partition properties 
which result in enhanced membrane affinity and permeation [151]. Choline ampicillin is the 
most interesting compound resulting from this association as it presents adequate solubility 
and low toxicity. In terms of bacterial resistance reversion, the compound with highest 
potential is cetylpyridinium ampicillin [152]. Another interesting approach, explored since the 
first experiences with IL-APIs through the use of docusate [14], is to couple a bioactive ion 
with a well-known excipient as counterion. A good example is the synthesis of tetracycline 
docusate to modulate important biopharmaceutical properties of tetracycline [153]. Even 
though the solubility of the drug decreases to half on the IL format, both octanol-water and 
liposome-water partition coefficients show a favorable trend concerning in vivo activity. This 
approach is also very well illustrated by the synthesis of stable IL-APIs based on 
benzethonium and propantheline combined with artificial sweeteners such as acesulfamate, 
saccharinate and p-toluenesulfonate, via metathesis reaction [144, 154, 155]. The obtained 
compounds overcome issues of polymorphism, typical for instance of propantheline bromide 
and modify the thermal properties and solubility of the compounds. The utilization of 
sweeteners can be also interesting to camouflage the unpleasant taste of specific APIs being 
good options to integrate oral formulations.  
Distinctly, the advantages of the liquid properties of an IL can be combined with the 
benefits of solid state by means of the immobilization of IL-APIs on mesoporous silica [146]. 
The study of the sorption, stability and release profile of tetrabutylphosphonium ibuprofenate 
and lidocainium ibuprofenate confirm that this strategy can be a tool for drug delivery with 
the ability to control the release of the adsorbed compound by manipulating the IL properties. 
There are evidences of total and fast leaching of the IL-API in physiological conditions 
(phosphate buffer saline, pH 7.4, 37ºC) and enhanced thermal stability of the IL-API 
compared with its liquid form. 
The prodrug approach is also a possibility when dealing with pharmaceutically active ILs 
[147]. Prodrugs are pharmacologically inactive derivatives of a related drug molecule that 
demand a spontaneous or enzymatic transformation in vivo to release the active drug. They 
can be idealized to overcome pharmaceutical, pharmacokinetic, or pharmacodynamic 
problems such as chemical instability, reduced solubility, unacceptable taste or odor, 
insufficient oral absorption, inadequate blood-brain barrier permeability and toxicity, among 
others [162]. The combination of an IL strategy with the prodrug approach can be an 
important tool for the development of APIs with improved properties and higher possibilities 
to actuate efficiently in vivo. This was explored through the functionalization of 
acetaminophen (paracetamol) through esterification with chloroacetyl chloride to obtain a 
neutral acetoxy derivative [147]. This was subjected to further alkylation with typical IL 
precursors to form chloride salts or to anion exchange with silver docusate to obtain prodrug 
docusate ILs. This new prodrugs present low water solubility and are readily hydrolyzed in 
physiological conditions suggesting good bioactivity.  
This section could not be closed without a mention to the importance of protic ILs (PILs) 
in the pharmaceutical field, namely as APIs. PILs are a subclass of ILs formed by the reaction 
of a Brønsted acid with a Brønsted base [100]. The main difference between PILs and other 
ILs is the proton transfer from the acid to the base that originates proton-donor and -acceptor 
sites, which can be used to build up a hydrogen-bonded network. The simplicity of the 
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synthetic route for the production of PILs makes these compounds very promising for 
pharmaceutical applications [145, 156, 157, 163]. It is then possible to obtain PIL-APIs from 
acids and bases commonly used in the pharmaceutical industry. As examples, salicylic, 
benzoic and gentisic acids can form PIL-APIs through the combination with pharmaceutical 
bases such as tuaminoheptane, amantadine and 2-pyrrolidinoethanol, ethylamine and 
diethylamine, among others [156, 164]. The variable properties of the obtained compounds 
can be explored to modulate their membrane permeation. Studies with model membranes 
suggest that PIL-APIs with low ionicity can readily cross the lipid bilayer, probably as 
hydrogen bond complexes [157, 164]. Considering that PIL-APIs exist mainly as ion-pairs 
their behavior is similar to that of neutral species and thus can cross membranes more easily 
than ionic species. It is also possible that, proton transfer, at the point of dissolution into the 
membrane, plays a key role in the transport.  
Even though it is controversial, in this group of compounds one can also include 
oligomeric ILs that result from the combination of non-stoichiometric ratios of the selected 
acids and bases [165]. This results in the formation of hydrogen-bonded moieties containing 
both ions and some neutral non-ionized compound. Thus, the composition of these liquids can 
range from fully ionized to partially ionized or non-ionized species generating intensive 
debate regarding the classification of these compounds. These are proton transfer IL systems 
in which the proton is shared by two or more cationic or anionic moieties leading to a 
controlled reduction of melting point with expansion of the liquid range. Oligomerization can 
be also applied to the formation of pharmaceutically active compounds as demonstrated by 
Bica and Rogers through the synthesis of oligomeric tetrabutylphosphonium salicylates and 
lidocainium salicylate [13, 163].  
Recently, MEDRx Co. Ltd. (a Japanese pharmaceuticals company) and IL Pharma Inc. (a 
subsidiary of MEDRx Co., Ltd.) developed an etodolac-lidocaine patch (MRX-7EAT) for the 
treatment of pain and inflammation using ILTS® (Ionic Liquid Transdermal System) [158-
160]. The patch presents higher skin permeability than the conventional etodolac patch with a 
consequent increase of the systemic exposure to etodolac. The results of non-clinical and 
clinical studies confirmed the safety and tolerability of the product [159, 160]. 
Considering the future pharmaceutical utilization of IL-APIs the toxicity and 
biodegradability of these compounds must be carefully evaluated and discussed as usually 
performed with conventional pharmaceutical drugs. Even though this compounds are 
synthesized from GRAS materials, the evaluation of toxicity must include the study of their 
effects on humans as well as their environmental impact since the principal pathway for their 
release is the aquatic environment due to their low volatility. Up to now there is very few 
information concerning the issues of toxicity and biodegradability and the available data 
refers to in vitro assays based on human carboxylesterase and Vibrio fischeri [149]. The effect 
of the abovementioned salicylates [148] on aquatic bacteria Vibrio fischeri ranges from 
practically harmless to slightly toxic. Due to its antimicrobial activity compounds 
incorporating the cetylpyridinium cation tend to be more toxic for both humans and the 
aquatic environment than those incorporating benzethonium and benzalkonium. These 
salicylates are only slightly more toxic than their original starting materials. This marginally 
enlarged risk is totally compensated by the benefits that accrue from the dual activity of the 
compounds. Interestingly, the anion bistriflimide can modulate the toxicity of the IL-APIs. 
For instance, the toxicity of benzethonium and phosphonium cations is decrease when 
combined with bistriflimide to form an IL-API. Not surprisingly, the toxicity of IL-APIs 
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resulting from the association of benzethonium or trihexyltetradecylphosphonium with the 
docusate anion is related almost exclusively to the toxicity of the cations, due to the 
innocuous nature of this anion.  
 
 
4. FINAL REMARKS AND FUTURE TRENDS 
 
The pharmaceutical utilization of ILs either as solvents, carriers or APIs has increased in 
the last years with successful examples both at the industrial and academic level. 
The peculiar properties of ILs are of pivotal importance for their application as 
substitutes of conventional VOCs during the synthesis of pharmaceutical drugs and in other 
phases of pharmaceutical processing. With adequate compound selection the use of ILs as 
pharmaceutical solvents can result on a significant reduction of the human and environmental 
impact of pharmaceutical synthesis while providing higher yield synthetic routes as described 
for biocatalytic synthesis. The appearance of greener ILs with more attractive properties in 
terms of toxicity and biodegradability further foments their incorporation in pharmaceutical 
formulations as part of drug delivery systems with improved properties in terms of drug 
release profile and pharmacologic activity. This seems to be one of the most promising 
application of ILs in a near future being a full acceptance of this approach mainly dependent 
on the abovementioned toxicity concerns and on evidences of adequate pharmaceutical 
profiles of the involved drugs. 
Despite the high resistance of the pharmaceutical industry to this concept, the synthesis of 
APIs with IL properties is undoubtfully the most exciting and captivating application in this 
field. The possibility of obtaining dual activity compounds or drugs with improved properties 
either concerning their efficiency or their undesirable effects opens countless possibilities for 
drugs with reduced bioavailability and for the treatment of diseases with particular and 
complex demands in terms of pharmacological intervention. The recent advances with IL-API 
prodrugs further enhances these possibilities. Studies with pharmaceutically active silica 
supported ILs offer also promising perspectives in the field of nanotechnology, mainly 
through the association of IL-APIs with nanoparticles for drug delivery. 
 The implementation of the IL strategy for the synthesis of novel drugs in the 
pharmaceutical industry demands only a deep change in mentalities of the involved 
institutions and the creation of specific tools to perform drug´s purification and manipulation 
on the liquid state. Legal and approval issues are largely facilitated by the well-known safe 
nature of the anions and cations used to synthesize novel IL-APIs. In conclusion, the 
conditions for the insertion of more products based on the IL-API concept in the 
pharmaceutical market are created and it is expect that once the abovementioned advantages 
are clearly evidenced by influential authorities the concept will disseminate rapidly. 
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